Figure 4.

Improvement of spontaneous alternation performance on Y-maze task using an Aβ(1–42)-infused mouse model injected with carprofen co-incubated with Aβ(1–42) monomer by peripheral administration. (a) The experimental scheme displaying the time course of sample incubation followed by the schematic brain region to show the ICV injection site of ICR mice (male, 7-week-old, n = 8/group) to create an Aβ(1 – 42)-infused mouse model, with reduced cognitive behavioral performance, followed by intraperitoneal injections of carprofen in prior to Y-maze test. (b) The percentage of spontaneous alternations and the total number of entries observed on Aβ(1 – 42)-infused ICR mice groups. The prepared groups are as following: vehicle (white, n = 8), 2-day Aβ(1– 42) aggregates (0.05 nmole in PBS, black, n = 8), and a second 2-day Aβ(1–42) aggregates group with three daily intraperitoneal injections of carprofen (25 mg/kg/day, red, n = 8). All data represent the mean ± SEM and the statistical analyses were performed by one-way analysis of variance with the comparison to 2-day Aβ(1 − 42) aggregates-treated group (black) (*P < 0.05, **P < 0.01, ***P < 0.001, other comparisons not significant). ICV, intracerebroventricular; ICR, imprinting control region; ip, intraperitoneal.